Innovative risk assessment for individualizing treatment in chronic lymphocytic leukemia

Project Information

CLLassify

Grant agreement ID: 702714

DOI

10.3030/702714

Project closed

EC signature date 8 March 2016

Start date 1 April 2016

End date 31 March 2018

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost

€ 164 653,20

EU contribution

€ 164 653,20

Coordinated by

ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS
Greece

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (2)

Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference

Author(s): P. Baliakas, A. Puiggros, A. Xochelli, L.-A. Sutton, F. Nguyen-Khac, A. Gardiner, K. Plevova, E. Minga, A. Hadzidimitriou, R. Walewska, H. McCarthy, M. Ortega, R. Collado, T. Gonzalez, I. Granada, E. Luno, J. Kota kova, T. Moysiadis, Z. Davis, N. Stavroyianni, A. Anagnostopoulos, J. C. Strefford, S. Pospisilova, F. Davi, A. Athanasiadou, R. Rosenquist, D. Oscier, B. Espinet, K. Stamatopoulos
Published in: Haematologica, Issue 101/7, 2016, Page(s) e299-e302, ISSN 0390-6078
Publisher: Ferrata Storti Foundation
DOI: 10.3324/haematol.2015.140202

The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia

Author(s): Nikos Papakonstantinou, Stavroula Ntoufa, Elisavet Chartomatsidou, Konstantia Kotta, Andreas Agathangelidis, Lefki Giassafaki, Tzeni Karamanli, Panagiota Bele, Theodoros Moysiadis, Panagiotis Baliakas, Lesley Ann Sutton, Niki Stavroyianni, Achilles Anagnostopoulos, Antonios M. Makris, Paolo Ghia, Richard Rosenquist, Kostas Stamatopoulos
Published in: Oncotarget, Issue 7/24, 2016, Page(s) 35946–35959, ISSN 1949-2553
Publisher: Impact Journals
DOI: 10.18632/oncotarget.9371